GENFIT, a biopharmaceutical company focused on rare liver diseases, released its 2026 extra-financial performance report for the 2025 fiscal year. The report details the company's ESG initiatives, including over 30 projects involving employees, strong social engagement with nearly 90% employee participation, and maintaining a high gender equality index score of 88. GENFIT also achieved B Corp certification in 2025, reflecting its commitment to ethical practices and patient advocacy. The company plans to continue its ESG roadmap in 2026, aiming to enhance patient care and operational sustainability.
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Data I/O Corporation announced it will release its financial results for the second quarter ending June 30, 2026, on July 30 after market close. The company will host a conference call at 2 p.m. PT/5 p.m. ET to discuss the results, accessible via pho...
